Tiziana Life Sciences Ltd (TLSA) News
Follow Tiziana Life Sciences Ltd (TLSA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial
Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial Tiziana Life Sc
EQUITY | Nov 05, 2026, 07:02 PM UTC
L
Tiziana Says Experimental MS Treatment Meets Main Goals in Mid-Stage Study
Tiziana Life Sciences said its experimental therapy reduced brain inflammation and showed a favorable safety profile in a mid-stage trial for progressive multiple sclerosis.
EQUITY | Nov 02, 2026, 12:42 PM UTC
L
Tiziana Reports Positive Phase 2a INFORM-MS Trial Results
Tiziana reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
EQUITY | Nov 02, 2026, 12:09 PM UTC
L
Tiziana Life Sciences, Ltd. (TLSA) Files For FDA Orphan Drug Designation In MSA
Tiziana Life Sciences filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy. A Phase 2a open-label MSA study is underway assessing microglial activation, clinical outcomes, and s
REGULATION | Sep 30, 2026, 11:09 AM UTC
L
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development can
REGULATION | Sep 30, 2026, 11:08 AM UTC
L
Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Tiziana Life Sciences Ltd NASDAQ:TLSA
REGULATION | Sep 30, 2026, 11:01 AM UTC
L
Tiziana Life Sciences, Ltd. (TLSA) Doses First ALS Patients in Phase 2a Trial
Tiziana Life Sciences dosed the first three participants with intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN trial, evaluating biomarker effects and safety in ALS.Material DetailsContext by AI AnalystThis
NEWS | Sep 28, 2026, 11:09 AM UTC
L
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development can
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Weekly Recap: Foralumab Phase 2a completion and BTIG $7.00 target
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) announced the final patient completed the Phase 2a INFORM—MS intranasal Foralumab trial in non—active SPMS with a database lock this week and 12—week topline data due October 2026
NEWS | Sep 28, 2026, 11:06 AM UTC
M
Tiziana says last patient completed last visit in phase 2A trial
Tiziana Life Sciences said the last patient completed the last visit in its Phase 2A Inform-MS trial of intranasal foralumab.
EQUITY | Sep 21, 2026, 12:07 PM UTC
L
TLSA - Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
TLSA - Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
NEWS | Sep 21, 2026, 11:00 AM UTC
L
TLSA - Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
TLSA - Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
NEWS | Sep 17, 2026, 11:00 AM UTC
L
Tiziana Life Sciences Initiated at Buy by BTIG
Ratings actions from Benzinga
EQUITY | Sep 03, 2026, 10:18 AM UTC
L
Tiziana Life Sciences to present Phase 2a BANYAN poster
Tiziana Life Sciences (TLSA) announces a poster presentation at ALS Nexus 2026 covering its Phase 2a BANYAN clinical trial of intranasal foralumab.
EQUITY | Aug 24, 2026, 11:00 AM UTC
L
Tiziana Life Sciences CEO Elrifi Sells 321,423 Shares
Tiziana Life Sciences CEO sells shares
EQUITY | Aug 06, 2026, 01:31 PM UTC
L
Tiziana Life Sciences CEO Buys Shares
CEO purchases company shares
EQUITY | Aug 06, 2026, 11:01 AM UTC
H
Insiders Buy $13M+ in BSX, HLI, IR, PFE, WCC, TLSA, TSCO
Insiders purchase over $13 million in company shares
EQUITY | Aug 06, 2026, 09:19 AM UTC
L
Tiziana Life Sciences CEO Buys Shares
CEO purchases company shares
EQUITY | Aug 04, 2026, 11:01 AM UTC
H
TLSA Reports Reduction in Brain Inflammation
TLSA treats third patient with reduced brain inflammation
EQUITY | Jul 31, 2026, 11:00 AM UTC
M
TLSA Completes Dosing
Tiziana announces last patient successfully dosed in its Phase 2 INFORM-MS trial
EQUITY | Jun 25, 2026, 11:00 AM UTC